Literature DB >> 24708941

The role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to C. difficile infection: a case-control study.

J Islam1, A L Taylor1, K Rao2, G Huffnagle3, V B Young3, C Rajkumar4, J Cohen1, P Papatheodorou5, D M Aronoff3, M J Llewelyn6.   

Abstract

Antibody levels to Clostridium difficile toxin A (TcdA), but not toxin B (TcdB), have been found to determine risk of C. difficile infection (CDI). Historically, TcdA was thought to be the key virulence factor; however the importance of TcdB in disease is now established. We re-evaluated the role of antibodies to TcdA and TcdB in determining patient susceptibility to CDI in two separate patient cohorts. In contrast to earlier studies, we find that CDI patients have lower pre-existing IgA titres to TcdB, but not TcdA, when compared to control patients. Our findings suggest that mucosal immunity to TcdB may be important in the early stages of infection and identifies a possible target for preventing CDI progression.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  Case–control study; Clostridium difficile; Humoral immune response; Toxin A (TcdA); Toxin B (TcdB)

Mesh:

Substances:

Year:  2014        PMID: 24708941      PMCID: PMC4140433          DOI: 10.1016/j.anaerobe.2014.03.011

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  26 in total

1.  Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom.

Authors:  Vhairi Wilson; Liz Cheek; Giovanni Satta; Karen Walker-Bone; Marc Cubbon; Diane Citron; Dale N Gerding; Martin J Llewelyn
Journal:  Clin Infect Dis       Date:  2010-06-15       Impact factor: 9.079

2.  Nosocomial acquisition of Clostridium difficile infection.

Authors:  L V McFarland; M E Mulligan; R Y Kwok; W E Stamm
Journal:  N Engl J Med       Date:  1989-01-26       Impact factor: 91.245

Review 3.  The changing epidemiology of Clostridium difficile infections.

Authors:  J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 4.  Toxin A-negative, toxin B-positive Clostridium difficile.

Authors:  Denise Drudy; Séamus Fanning; Lorraine Kyne
Journal:  Int J Infect Dis       Date:  2006-07-20       Impact factor: 3.623

5.  Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents.

Authors:  Michelle M Riggs; Ajay K Sethi; Trina F Zabarsky; Elizabeth C Eckstein; Robin L P Jump; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2007-09-04       Impact factor: 9.079

6.  Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile.

Authors:  Jordi M Lanis; Soumitra Barua; Jimmy D Ballard
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

7.  Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).

Authors:  Brett A Leav; Barbra Blair; Mark Leney; Michael Knauber; Courtney Reilly; Israel Lowy; Dale N Gerding; Ciarán P Kelly; Kia Katchar; Roger Baxter; Donna Ambrosino; Deborah Molrine
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

8.  Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.

Authors:  S Johnson; D N Gerding; E N Janoff
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

9.  Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium.

Authors:  Guilin Yang; Boping Zhou; Jufang Wang; Xiangyun He; Xingmin Sun; Weijia Nie; Saul Tzipori; Hanping Feng
Journal:  BMC Microbiol       Date:  2008-11-06       Impact factor: 3.605

10.  Toxin B is essential for virulence of Clostridium difficile.

Authors:  Dena Lyras; Jennifer R O'Connor; Pauline M Howarth; Susan P Sambol; Glen P Carter; Tongted Phumoonna; Rachael Poon; Vicki Adams; Gayatri Vedantam; Stuart Johnson; Dale N Gerding; Julian I Rood
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

View more
  7 in total

Review 1.  Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.

Authors:  L Patrick Schenck; Paul L Beck; Justin A MacDonald
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

2.  A human gut ecosystem protects against C. difficile disease by targeting TcdA.

Authors:  Sarah Lynn Martz; Mabel Guzman-Rodriguez; Shu-Mei He; Curtis Noordhof; David John Hurlbut; Gregory Brian Gloor; Christian Carlucci; Scott Weese; Emma Allen-Vercoe; Jun Sun; Erika Chiong Claud; Elaine Olga Petrof
Journal:  J Gastroenterol       Date:  2016-06-21       Impact factor: 7.527

Review 3.  From Nursery to Nursing Home: Emerging Concepts in Clostridioides difficile Pathogenesis.

Authors:  Alexander B Smith; Joshua Soto Ocana; Joseph P Zackular
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

4.  Blastocystis and Clostridioides difficile: Evidence for a Synergistic Role in Colonization Among IBD Patients with Emphasis on Ulcerative Colitis.

Authors:  Masoumeh Azimirad; Sara Mohammad Ali Gol; Ehsan Javanmard; Hamed Mirjalali; Abbas Yadegar; Hamid Asadzadeh Aghdaei; Shabnam Shahrokh; Hedieh Balaii; Amir Sadeghi; Mohammad Reza Zali
Journal:  Turk J Gastroenterol       Date:  2021-06       Impact factor: 1.852

Review 5.  Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.

Authors:  Nancy Fu; Titus Wong
Journal:  Curr Infect Dis Rep       Date:  2016-06       Impact factor: 3.725

Review 6.  Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects.

Authors:  Stefano Di Bella; Paolo Ascenzi; Steven Siarakas; Nicola Petrosillo; Alessandra di Masi
Journal:  Toxins (Basel)       Date:  2016-05-03       Impact factor: 4.546

7.  High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection.

Authors:  Tanya M Monaghan; Ola H Negm; Brendon MacKenzie; Mohamed R Hamed; Clifford C Shone; David P Humphreys; K Ravi Acharya; Mark H Wilcox
Journal:  Clin Exp Gastroenterol       Date:  2017-07-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.